CN102940686B - 川楝子提取物在制备抗病毒药物中的应用及其提取方法 - Google Patents
川楝子提取物在制备抗病毒药物中的应用及其提取方法 Download PDFInfo
- Publication number
- CN102940686B CN102940686B CN201210389839.XA CN201210389839A CN102940686B CN 102940686 B CN102940686 B CN 102940686B CN 201210389839 A CN201210389839 A CN 201210389839A CN 102940686 B CN102940686 B CN 102940686B
- Authority
- CN
- China
- Prior art keywords
- fructus toosendan
- virus
- extract
- toosendan extract
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000284 extract Substances 0.000 title claims abstract description 54
- 238000002360 preparation method Methods 0.000 title claims description 9
- 239000003443 antiviral agent Substances 0.000 title claims description 7
- 238000000034 method Methods 0.000 title abstract description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 21
- 241000711975 Vesicular stomatitis virus Species 0.000 claims abstract description 13
- 241000712461 unidentified influenza virus Species 0.000 claims abstract description 11
- 238000010992 reflux Methods 0.000 claims abstract description 8
- 239000011347 resin Substances 0.000 claims abstract description 8
- 229920005989 resin Polymers 0.000 claims abstract description 8
- 230000000274 adsorptive effect Effects 0.000 claims abstract description 4
- 241000700605 Viruses Species 0.000 claims description 22
- 239000003814 drug Substances 0.000 abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 10
- 230000003602 anti-herpes Effects 0.000 abstract description 3
- 230000002155 anti-virotic effect Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 25
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 11
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 230000001629 suppression Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 208000000440 Herpetic Stomatitis Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010067152 Oral herpes Diseases 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 239000010413 mother solution Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- 208000001688 Herpes Genitalis Diseases 0.000 description 3
- NAHTXVIXCMUDLF-DUJPAFNYSA-N Toosendanin Natural products O=C(O[C@H]1C(=O)[C@H]2[C@@](C)([C@H](O)C[C@H]3[C@@]4(C)[C@H](O)OC[C@@]23[C@@H](O)C[C@H]4OC(=O)C)[C@@]23[C@]1(C)[C@H](c1cocc1)C[C@H]2O3)C NAHTXVIXCMUDLF-DUJPAFNYSA-N 0.000 description 3
- 239000003463 adsorbent Substances 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000006837 decompression Effects 0.000 description 3
- 206010014599 encephalitis Diseases 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 201000004946 genital herpes Diseases 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- NAHTXVIXCMUDLF-RFNFAWMESA-N toosendanin Chemical compound C=1([C@H]2[C@]3(C)[C@@H](OC(C)=O)C(=O)[C@H]4[C@@]([C@@]53O[C@@H]5C2)(C)[C@H](O)C[C@H]2[C@@]3(C)[C@H](O)OC[C@]24[C@@H](O)C[C@H]3OC(=O)C)C=COC=1 NAHTXVIXCMUDLF-RFNFAWMESA-N 0.000 description 3
- 239000008488 toosendanin Substances 0.000 description 3
- 241001529453 unidentified herpesvirus Species 0.000 description 3
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- 241000282552 Chlorocebus aethiops Species 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000005100 Herpetic Keratitis Diseases 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 241000712431 Influenza A virus Species 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 description 2
- -1 absorption carrier Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 239000002024 ethyl acetate extract Substances 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 201000010884 herpes simplex virus keratitis Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003508 Botulism Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700628 Chordopoxvirinae Species 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000713196 Influenza B virus Species 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 241001500343 Influenzavirus C Species 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000158728 Meliaceae Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 241000711931 Rhabdoviridae Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010043866 Tinea capitis Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 241000711970 Vesiculovirus Species 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000012928 buffer substance Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 229940124447 delivery agent Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000001268 lymphoproliferative syndrome Diseases 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- ZADYMNAVLSWLEQ-UHFFFAOYSA-N magnesium;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[Mg+2].[Si+4] ZADYMNAVLSWLEQ-UHFFFAOYSA-N 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 210000001034 respiratory center Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种川楝子提取物的提取方法,所述方法包括如下步骤:(a)将川楝子用乙醇回流提取;(b)用大孔吸附树脂柱纯化。本发明的川楝子提取物具有较好的抗病毒作用,可用于制备抗疱疹病毒、水疱性口炎病毒及流感病毒药物或药物组合物。
Description
技术领域
本发明属于医药技术领域,具体涉及川楝子提取物在制备抗病毒药物中的应用以及该川楝子提取物的提取方法。
背景技术
川楝子又名金铃子,中药材,为楝科落叶乔木川楝树MeliatoosendanSieb.etZucc.的干燥成熟果实,含川楝素、生物碱、山柰醇、树脂、鞣质等,临床主要用于治疗急性乳腺炎、头癣等。现代药理学研究表明,川楝子中的川楝素具有驱虫作用(中国兽药杂志,2008,42(3):28-31)、对呼吸中枢的抑制作用及抗肉毒中毒作用(中草药杂志,1982,13(6):29-30),另有文献报道,川楝子醇提取物具有抗甲型流感病毒H1N1的活性(时珍国医国药,2011,22(8):1832-1834),川楝子的乙酸乙酯提取物具有抗HSV-1病毒的活性(中药新药与临床药理,2010,21(1):7-10)。
单纯疱疹病毒HSV(Herpessimplexvirus)属于疱疹病毒科a病毒亚科,根据抗原性的差别分为1型和2型(HSV-1和HSV-2),可引起口唇性疱疹、疱疹性角膜炎、疱疹性皮肤炎、阴部疱疹、卡波西病等,有时也是脑膜炎、脑炎的病因,HSV-1常引起腰部以上感染,尤其眼及口腔部位的感染,HSV-1也能引起生殖器疱疹(10%)。
水疱性口炎病毒VSV(Vesicularstomatitisvirus)为弹状病毒科、水疱病毒属的成员,为单股负链RNA病毒,可引起水疱性口炎等疾病。水疱性口炎是多种哺乳动物的一种急性高度接触性传染病。以马、牛、猪等动物较易感,绵羊和山羊也可感染。人也偶有感染,引起流感样症状,严重者可引起脑炎。本病被国际兽疫局(OIE)列为A类疾病,在我国水疱性口炎为外来动物病,国家进出境动物检疫对象中将VSV列为二类疫病。
流行性感冒病毒,简称流感病毒,是一种造成人类及动物患流行性感冒的RNA病毒,在分类学上,流感病毒属于正黏液病毒科,它会造成急性上呼吸道感染,并借由空气迅速的传播,在世界各地常会有周期性的大流行。流行性感冒病毒在免疫力较弱的老人或小孩及一些免疫失调的病人会引起较严重的症状,如肺炎或是心肺衰竭等。人类流感病毒根据其核蛋白的抗原性可分为3类:甲型流感病毒、乙型流感病毒和丙型流感病毒,其中WSN病毒属于甲型流感病毒。
MHV68是鼠γ疱疹病毒68,是研究γ疱疹病毒的一个很有价值的动物模型,γ疱疹病毒与一些恶性肿瘤密切相关,如Burkitt’s淋巴瘤、鼻咽癌、Hodgkin’s病、器官移植后淋巴组织增生症及AIDS相关B淋巴瘤。
发明内容
本发明的申请人在川楝子的研究中意外地发现应用本发明的提取方法制备的川楝子提取物在体外可显著抑制单纯疱疹病毒HSV-1,其抑制HSV-1的IC50是背景技术中提到的川楝子的乙酸乙酯提取物的IC50的1/15,活性大大增强。此外,本发明的申请人还发现应用本发明的提取方法制备的川楝子提取物在体外还可显著抑制水疱性口炎病毒VSV、流感病毒WSN和鼠疱疹病毒68(MHV68)。
本发明的一个目的在于提供一种优选的川楝子提取物的提取方法,所述方法包括如下步骤:
(a)将川楝子用乙醇回流提取;
(b)用大孔吸附树脂柱纯化。
其中,所述步骤(a)包括:将川楝子用50%~90%乙醇回流提取1~3次,每次1~3小时。所述步骤(b)包括:将所述步骤(a)中的提取物过滤后离心,取上清液上大孔吸附树脂柱,先以蒸馏水洗脱,再以30%~90%乙醇梯度洗脱,收集洗脱液,洗脱液减压浓缩、冷冻干燥。
本发明的另一个目的在于提供应用上述提取方法制备的川楝子提取物。
本发明的另一个目的在于提供应用上述提取方法制备的川楝子提取物用于制备抗病毒药物的应用。
特别是,川楝子提取物在制备抗疱疹病毒、水疱性口炎病毒及流感病毒药物中的应用。
此外,本发明的目的还在于提供一种药物组合物,包括治疗有效量的所述川楝子提取物及至少一种可药用载体。“治疗有效量”是指能够达到治疗效果的提取物的量。本领域的技术人员能够理解“治疗有效量”可以随着给药的方式、载体的使用以及可能和其他治疗剂合用等而有所不同。较佳地,本发明的药物组合物含有0.1-99.9%重量百分比的作为活性成分的本发明的川楝子提取物。“可药用载体”不会破坏本发明的川楝子提取物的药学活性,同时其有效用量,即能发挥药物载体作用时的用量对人体无毒。所述可药用载体包括但不限于:软磷脂、硬脂酸铝、氧化铝、离子交换材料、自乳化药物传递系统、吐温或其他表面活化剂、血清蛋白、缓冲物质如磷酸盐、氨基乙酸、山梨酸、水、盐、电解质如硫酸盐精蛋白、磷酸氢二钠、磷酸氢钾、氯化钠、锌盐、硅酸镁、饱和脂肪酸部分甘油酯混合物等。
本发明的药物组合物还可包括一种或多种常用的药物辅料,如粘合剂(如微晶纤维素)、填充剂(如淀粉、葡萄糖、无水乳糖和乳糖珠粒)、崩解剂(如交联PVP、交联羧甲基淀粉钠、交联羧甲基纤维素钠、低取代羟丙基纤维素)、润滑剂(如硬脂酸镁)以及吸收促进剂、吸附载体、香味剂、甜味剂、赋形剂、稀释剂、润湿剂等。
所述药物组合物可按本领域常规方法制备并可以通过肠道或非肠道或局部途径给药。口服制剂包括片剂、颗粒剂、悬浮液、胶囊、溶液等,非肠道给药制剂包括注射液。局部给药制剂包括霜剂、贴剂、软膏剂、喷雾剂、凝胶剂等。
所述川楝子提取物以及药物组合物的给药途径可以为口服、舌下、经皮、经肌肉或皮下、皮肤粘膜、静脉、尿道、阴道等。
所述川楝子提取物及药物组合物的用量可根据给药途径、患者的年龄和体重、病症严重程度的不同而不同,其日剂量可以是0.001~100mg/kg,可以一次或多次给药。
本发明进一步提出川楝子提取物或以其为基本活性成分的组合物在预防和治疗各种由病毒引起的疾病中的用途,这种由病毒引起的疾病包括口唇性疱疹、疱疹性角膜炎、疱疹性皮肤炎、生殖器疱疹、卡波西病、脑膜炎、脑炎、水疱性口炎、病毒性感冒等。
本发明的有益效果:在本申请的研究中发现,应用本发明的提取方法制备的川楝子提取物对HSV-1、VSV、WSN、MHV68均有较强的抑制作用,说明本发明的川楝子提取物具有较好的抗病毒作用,可用于制备抗疱疹病毒、水疱性口炎病毒及流感病毒药物或药物组合物。
具体实施方式
以下结合具体实施例,对本发明作进一步说明。应理解,以下实施例仅用于说明本发明而非用于限定本发明的范围。
实施例1、川楝子提取物的制备
取药材粗粉200g,加10倍量50%的乙醇回流提取1次,1h/次,过滤。合并滤液,滤液减压浓缩至每毫升相当于0.5g生药,浓缩液离心(3000r/min,15min)得上清液,再将上清液加入6倍量的大孔吸附树脂AB8柱上,上样流速为4BV/h,先以6倍柱体积蒸馏水洗脱,再依次以6倍柱体积30%~90%乙醇梯度洗脱,收集洗脱液,加压浓缩适量,然后减压冷冻干燥至干,粉碎得川楝子提取物4.5g。
实施例2、川楝子提取物的制备
取药材粗粉200g,加10倍量70%的乙醇回流提取3次,2h/次,过滤。合并滤液,滤液减压浓缩至每毫升相当于0.5g生药,浓缩液离心(3000r/min,15min)得上清液,再将上清液加入6倍量的大孔吸附树脂HP-20柱上,上样流速为6BV/h,先以6倍柱体积蒸馏水洗脱,再依次以6倍柱体积30%~90%乙醇梯度洗脱,收集洗脱液,加压浓缩适量,然后减压冷冻干燥至干,粉碎得川楝子提取物6.4g。
实施例3、川楝子提取物的制备
取药材粗粉200g,加10倍量90%的乙醇回流提取2次,3h/次,过滤。合并滤液,滤液减压浓缩至每毫升相当于0.5g生药,浓缩液离心(3000r/min,15min)得上清液,再将上清液加入6倍量的大孔吸附树脂D101柱上,上样流速为5BV/h,先以6倍柱体积蒸馏水洗脱,再依次以6倍柱体积30%~90%乙醇梯度洗脱,收集洗脱液,加压浓缩适量,然后减压冷冻干燥至干,粉碎得川楝子提取物7.2g。
实施例4、川楝子提取物对HSV-1病毒的抑制作用
实验材料:
细胞:非洲绿猴肾细胞(Vero细胞),购自中科院细胞库。
病毒:HSV-1-GFP。
受试药物:川楝子提取物(按实施例1方法制备),溶解于DMSO中,制备得60mg/mL母液。
实验方法:
Vero细胞按常规方法培养,次日接种于96孔板,待细胞贴壁后,以HSV-1-GFP病毒感染细胞,3小时后,去除含病毒培养液,以一定浓度的川楝子萜类处理细胞,22小时后荧光显微镜下观察GFP蛋白表达情况。同时以0.4μg/mL的阿昔洛韦(ACV)处理细胞作为阳性对照。
实验结果如以下表1所示。
表1、川楝子提取物对HSV-1病毒的抑制
以上表1的实验结果表明,在非洲绿猴肾细胞中川楝子提取物对HSV-1具有明显的抑制作用,且川楝子提取物对HSV-1的抑制呈剂量依赖关系。
实施例5、川楝子提取物对VSV病毒的抑制作用
实验材料:
细胞:人肺腺癌细胞(A549),购自中科院细胞库。
病毒:VSV-GFP。
受试药物:川楝子提取物(按实施例2方法制备),溶解于DMSO中,制备得60mg/mL母液。
实验方法:
A549细胞按常规方法培养,次日接种于96孔板,待细胞贴壁后,以VSV-GFP病毒感染细胞,1小时后,去除含病毒培养液,以一定浓度的川楝子提取物处理细胞,18小时后荧光显微镜下观察GFP蛋白表达情况。同时以3IU/mL的干扰素α(IFNα)处理细胞作为阳性对照。
实验结果如以下表2所示。
表2、川楝子提取物对VSV病毒的抑制
以上表2的实验结果表明,在人肺腺癌细胞中川楝子提取物对VSV病毒具有明显的抑制作用,且川楝子提取物对VSV的抑制呈剂量依赖关系。
实施例6、川楝子提取物对WSN病毒的抑制作用
实验材料:
细胞:人胚肾细胞(293T),购自ATCC。
病毒:WSN。
受试药物:川楝子提取物(按实施例2方法制备),溶解于DMSO中,制备得60mg/mL母液。
实验方法:
293T细胞按常规方法培养,次日接种于96孔板,待细胞贴壁后,以一定浓度的川楝子提取物处理细胞,6小时后去除药液,以WSN病毒感染细胞,1小时后,去除含病毒培养液,更换成新鲜培养基,8小时后观察结果。
实验结果如以下表3所示。
表3、川楝子提取物对WSN病毒的抑制
以上表3的实验结果表明,川楝子提取物对WSN病毒有较好的抑制作用,且呈剂量依赖关系。
实施例7、川楝子提取物对MHV68病毒的抑制作用
实验材料:
细胞:人胚肾细胞(293T),购自ATCC。
病毒:MHV68。
受试药物:川楝子提取物(按实施例3方法制备),溶解于DMSO中,制备得60mg/mL母液。
实验方法:
293T细胞按常规方法培养,次日接种于96孔板,待细胞贴壁后,以一定浓度的川楝子提取物处理细胞,8小时后去除药液,以MHV68病毒感染细胞,1小时后观察结果。
实验结果如以下表4所示。
表4、川楝子提取物对MHV68病毒的抑制
药物剂量(μg/mL) | 抑制率% | |
川楝子提取物 | 10 | 92.8 |
以上表4的实验结果表明,川楝子提取物对MHV68病毒具有很强的抑制作用。
综上所述,本发明的川楝子提取物对于多种病毒均具有良好的抑制作用,可用于制备抗病毒药物,或者进一步制成抗病毒的药物组合物,除了以治疗有效量的川楝子萜类为活性成分外,所述药物组合物还包括一种或多种可药用载体,所述可药用载体可以选用本领域中已知的常规载体;此外,所述药物组合物还可以包括一种或多种常用的药物辅料,这对于本领域的技术人员来说是显而易见的。
Claims (2)
1.川楝子提取物在制备抗病毒药物中的应用,其特征在于,所述病毒为水疱性口炎病毒和流行性感冒病毒,其中:
川楝子提取物通过如下步骤获得:
(a)将川楝子用乙醇回流提取;
(b)用大孔吸附树脂柱纯化;
所述步骤(a)包括:将川楝子用50%~90%乙醇回流提取1~3次,每次1~3小时。
2.如权利要求1所述的川楝子提取物在制备抗病毒药物中的应用,其特征在于,所述流行性感冒病毒为WSN病毒。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210389839.XA CN102940686B (zh) | 2012-10-15 | 2012-10-15 | 川楝子提取物在制备抗病毒药物中的应用及其提取方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210389839.XA CN102940686B (zh) | 2012-10-15 | 2012-10-15 | 川楝子提取物在制备抗病毒药物中的应用及其提取方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102940686A CN102940686A (zh) | 2013-02-27 |
CN102940686B true CN102940686B (zh) | 2016-08-03 |
Family
ID=47723746
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210389839.XA Expired - Fee Related CN102940686B (zh) | 2012-10-15 | 2012-10-15 | 川楝子提取物在制备抗病毒药物中的应用及其提取方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102940686B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104922214B (zh) * | 2015-06-08 | 2019-11-12 | 贵州大学 | 川楝子有效部位的应用及其制备方法 |
-
2012
- 2012-10-15 CN CN201210389839.XA patent/CN102940686B/zh not_active Expired - Fee Related
Non-Patent Citations (2)
Title |
---|
川楝子抑制破骨细胞活性组份的研究;周英,郭东贵,等;《中药材》;20090930;第32卷(第9期);1433-1435 * |
川楝子提取物体外抗单纯疱疹病毒1型活性的试验研究;赖志才,瞿畅,等;《中药新药与临床药理》;20100131;第21卷(第1期);7-10 * |
Also Published As
Publication number | Publication date |
---|---|
CN102940686A (zh) | 2013-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101361765B (zh) | 江南卷柏抗柯萨奇病毒和疱疹病毒提取物及提取工艺和制剂 | |
CN103768534B (zh) | 一种具有抗肿瘤活性的中药组合物 | |
CN106668832B (zh) | 一种多肽在制备治疗肠道病毒感染药物的应用 | |
US10675317B2 (en) | Use of ginseng extract, ginsenoside and ginsenoside derivative in the preparation of medicine or health care product for treating cytomegalovirus infection disorders | |
Lin et al. | Anti-viral activity of water extract of Paeonia lactiflora pallas against human respiratory syncytial virus in human respiratory tract cell lines | |
EP2606898B1 (en) | Composition comprising ligustroflavone, rhoifolin and hyperin, and use thereof in the preparation of a medicament | |
TWI453026B (zh) | 魚針草萃取物及其純化物抗流感病毒之用途 | |
TW200826954A (en) | Herbal extract with anti-influenza virus activity and preparation of same | |
CN102302484B (zh) | 异黄酮类化合物的用途 | |
KR20190059212A (ko) | 녹각 영지버섯 추출물 및 퀘르세틴을 유효성분으로 포함하는 엡스타인 바 바이러스-양성 위암 치료용 약학적 조성물 | |
CN102940686B (zh) | 川楝子提取物在制备抗病毒药物中的应用及其提取方法 | |
CN103040989A (zh) | 一种抗病毒的中药组合物及其制备方法 | |
WO2007059685A1 (fr) | Calycosine d'astragalus a fonction de resistance contre le coxackievirus | |
CN102670684B (zh) | 白薇总皂苷的应用 | |
JP2005502602A (ja) | ウイルス感染の治療用の医薬組成物 | |
WO2017129055A1 (zh) | 一种用于治疗脂肪肝、肝炎、肝硬化的药物 | |
KR101665015B1 (ko) | 복합 생약 추출물을 유효성분으로 함유하는 항바이러스용 조성물 | |
CN104771384B (zh) | 紫草素的医药用途 | |
CN114306354A (zh) | 一种具有抗2型登革病毒作用的植物单体及其应用 | |
JP6080479B2 (ja) | マイタケ抽出物由来の単純ヘルペスウイルス感染症の予防・治療剤 | |
CN111529565A (zh) | 一种抗流感病毒的制剂及其制备方法和应用 | |
KR101665016B1 (ko) | 복합 생약 추출물을 유효성분으로 함유하는 항바이러스용 조성물 | |
CN103893280B (zh) | 拳参提取物在制备抗病毒药物中的应用及其提取方法 | |
CN111773258B (zh) | 一种抗流感病毒的蒙药、药物组合物及其制备方法和应用 | |
CN107296827B (zh) | 一种抗甲型h1n1流感药物组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160803 |
|
CF01 | Termination of patent right due to non-payment of annual fee |